Literature DB >> 1373043

Sacral resection for control of pelvic tumors.

W J Temple1, A S Ketcham.   

Abstract

A surgical approach for treating patients with resected, recurrent, posterior pelvic visceral tumors involving the sacrum is detailed. Of 11 patients, 9 had rectal cancers, 1 had chordoma, and 1 had cancer of the cervix. Five total pelvic exenterations and five posterior exenterations were performed en bloc with involved sacrum. One patient had a sacral resection only. Surgical mortality was 9%, and the average hospital stay was 1 month. Mean disease-free survival was 1 year, and mean survival was 3 years. Absolute cure rate was 18% with a complete 5-year follow-up. This experience confirms the value of this procedure in selected patients.

Entities:  

Mesh:

Year:  1992        PMID: 1373043     DOI: 10.1016/0002-9610(92)90035-p

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  12 in total

1.  Mesh reconstruction preventing sacral herniation.

Authors:  K Junge; C J Krones; R Rosch; V Fackeldey; V Schumpelick
Journal:  Hernia       Date:  2003-07-18       Impact factor: 4.739

2.  En Bloc Resection with Partial Sacrectomy Helps to Achieve R0 Resection in Locally Advanced Rectal Cancer, Experience from a Tertiary Cancer Center.

Authors:  Nizamudheen M Pareekutty; Satheesan Balasubramanian; Sachin Kadam; Dipin Jayaprakash; Basavaraj Ankalkoti; Sangeetha Nayanar; Geetha Muttath; Bindu Anilkumar
Journal:  Indian J Surg Oncol       Date:  2019-01-09

3.  Prognostic factors affecting oncologic outcomes in patients with locally recurrent rectal cancer: impact of patterns of pelvic recurrence on curative resection.

Authors:  Jea-Kun Park; Young-Wan Kim; Hyuk Hur; Nam-Kyu Kim; Byung-Soh Min; Seung-Kook Sohn; Young-Deuk Choi; Young-Tae Kim; Jung-Bai Ahn; Jae-Kyung Roh; Ki-Chang Keum; Jin-Sil Seong
Journal:  Langenbecks Arch Surg       Date:  2008-07-29       Impact factor: 3.445

4.  Interstitial permanent implantation of 125I seeds as salvage therapy for re-recurrent rectal carcinoma.

Authors:  Jun Jie Wang; Hui Shu Yuan; Jin Na Li; Wei Juan Jiang; Yu Liang Jiang; Su Qing Tian
Journal:  Int J Colorectal Dis       Date:  2008-12-16       Impact factor: 2.571

5.  Management of recurrent rectal cancer: a population based study in greater Amsterdam.

Authors:  Roel Bakx; Otto Visser; Judith Josso; Sybren Meijer; J-Frederik-M Slors; J-Jan-B van Lanschot
Journal:  World J Gastroenterol       Date:  2008-10-21       Impact factor: 5.742

6.  CT-guided radioactive seed implantation for recurrent rectal carcinoma after multiple therapy.

Authors:  Jun Jie Wang; Hui Shu Yuan; Jin Na Li; Yu Liang Jiang; Su Qing Tian; Rui Jie Yang
Journal:  Med Oncol       Date:  2009-05-05       Impact factor: 3.064

7.  Perineal wound closure with the rectus abdominis musculocutaneous flap after tumor ablation.

Authors:  W G de Haas; M J Miller; W J Temple; S S Kroll; M A Schusterman; G P Reece; J M Skibber
Journal:  Ann Surg Oncol       Date:  1995-09       Impact factor: 5.344

8.  Biological and clinical availability of adipose-derived stem cells for pelvic dead space repair.

Authors:  Hidekazu Takahashi; Naotsugu Haraguchi; Shimpei Nishikawa; Susumu Miyazaki; Yozou Suzuki; Tsunekazu Mizushima; Junichi Nishimura; Ichirou Takemasa; Hirofumi Yamamoto; Koshi Mimori; Hideshi Ishii; Yuichiro Doki; Masaki Mori
Journal:  Stem Cells Transl Med       Date:  2012-10-23       Impact factor: 6.940

9.  Pelvic resection of recurrent rectal cancer.

Authors:  H J Wanebo; R J Koness; M P Vezeridis; S I Cohen; D E Wrobleski
Journal:  Ann Surg       Date:  1994-10       Impact factor: 12.969

10.  Preliminary results of phase I trial of oral uracil/tegafur (UFT), leucovorin plus irinotecan and radiation therapy for patients with locally recurrent rectal cancer.

Authors:  Masayoshi Yasui; Masataka Ikeda; Mitsugu Sekimoto; Hirofumi Yamamoto; Ichiro Takemasa; Takafumi Ueda; Junzo Shimizu; Mutsumi Fukunaga; Osamu Suzuki; Takehiro Inoue; Morito Monden
Journal:  World J Surg Oncol       Date:  2006-11-22       Impact factor: 2.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.